AI in Health Care: Balancing Benefits and Barriers
AI can help alleviate the burden on clinical labs—but only with sufficient investment, enthusiasm, and understanding
Diagnostic Testing and Emerging Technologies
Keeps You Up-to-Date on New Diagnostic Tests, Testing Trends and Opportunities, and Emerging Test Technologies
Esophageal Pre-Cancer Testing Gaining Greater Traction
How three companies are addressing screening challenges with tests that help improve chances of early detection
Computing the Future of the Lab
Computational biology expert Keaun Amani shares his advice and insights on AI and machine learning tools for the clinical lab
FDA’s Two Big Moves on NGS-Based Tumor Panels May Offer Clues for Alternative Pathways for LDT Approval
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
LDTs, FDA-Approved Companion Diagnostics Perform Similarly; Off-Label Use of Companion Diagnostic Kits Common
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
FDA Warns About Biotin Interference With Lab Tests
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Pediatric Offices Fail to Act on 1 in 10 Abnormal Test Results
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Foster Kids’ Standard Screenings Tests May Be of Low Value
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
AMP Issues Consensus Guidelines for NGS Bioinformatics Pipelines
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
FDA Continues Easing DTC, Home Use Test Regulations
From - Diagnostic Testing & Emerging Technologies
In a continued reversal of its 2013 crackdown on direct-to-consumer (DTC) genetic tests, the U.S. Food and Drug Administration (FDA) unveiled…
Novel Tests Emerging For Overlooked Conditions
From - Diagnostic Testing & Emerging Technologies
Undeniably, much of the emerging test focus is on cancer and infectious diseases. DTET wants to showcase other novel tests entering the marketplace. What follows is…
CMS Final Fee Schedule Will Impact Patient Access to Laboratories: COLA
From - Diagnostic Testing & Emerging Technologies
The CMS Final Fee Schedule will hurt patient access to clinical laboratories, says the lab accreditation bureau COLA…
Bilirubin as a Predictor of Neonatal Jaundice
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here